If OGT-activity promotes the development and progression of cancers with impaired p53 axes but decreased OGT-activity helps them live in harsh microenvironments, a useful strategy in such cases might involve brief treatments with OGT inhibitors followed by infusion of GlcN or OGA inhibitors to block survival processes induced by prior OGT-inhibition. Here, OGT is linked to cancer.